Cyclerion Therapeutics (CYCN) Net Cash Flow (2019 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Net Cash Flow of $1.6 million for Q3 2025, up 191.03% year-over-year from $536722.5 in Q3 2024, and up 346.76% quarter-over-quarter from -$633000.0 in Q2 2025.
Cyclerion Therapeutics (CYCN) Net Cash Flow (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $1.6 million for Q3 2025.
- In Q3 2025, Net Cash Flow rose 191.03% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.3 million (up 130.83% YoY), while the FY2024 annual figure was -$4.3 million, up 25.54% from the prior year.
- Net Cash Flow for Q3 2025 stood at $1.6 million, up from -$633000.0 in the prior quarter.
- The five-year high for Net Cash Flow was $25.1 million in Q2 2021, with the low at -$13.0 million in Q1 2021.
- The 5-year median for Net Cash Flow is -$1.9 million (2024), against an average of -$3.1 million.
- Peak annual rise in Net Cash Flow reached 336.5% in 2021, while the deepest fall reached 185.52% in 2021.
- Cyclerion Therapeutics' Net Cash Flow stood at -$8.5 million in 2021, then rose by 17.72% to -$7.0 million in 2022, then soared by 78.08% to -$1.5 million in 2023, then surged by 123.36% to $360000.0 in 2024, then jumped by 333.89% to $1.6 million in 2025.
- Business Quant data shows CYCN's Net Cash Flow at $1.6 million in Q3 2025, -$633000.0 in Q2 2025, and $407000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.56 Mn |
| Sep 30, 2025 | 1.56 Mn |
| Jun 30, 2025 | -633,000.00 |
| Jun 30, 2025 | -633,000.00 |
| Mar 31, 2025 | 407,000.00 |
| Mar 31, 2025 | 407,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2024 | -1.72 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -1.11 Mn |
| Jun 30, 2024 | -1.11 Mn |
| Mar 31, 2024 | -1.87 Mn |
| Mar 31, 2024 | -1.87 Mn |
| Dec 31, 2023 | -1.54 Mn |
| Dec 31, 2023 | -1.54 Mn |
| Sep 30, 2023 | 3.47 Mn |
| Sep 30, 2023 | 3.47 Mn |
| Jun 30, 2023 | -6.56 Mn |
| Jun 30, 2023 | -6.56 Mn |